Overview

A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)
Phase:
Phase 3
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Treatments:
Thyrotropin-Releasing Hormone